Τόμος 34 (2016) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 34 (2016) – Issue 3 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Γεώργιος Ιατράκης^1,2, Στέφανος Ζερβούδης^1,2, Αναστασία Μπόθου^2,3, Κυριάκος Μητσάκος-Μπαρμπαγιάννης², Σταύρος Φωτόπουλος², Παναγιώτης Πεϊτσίδης², Ειρήνη Τομαρά^2,3, Παναγιώτης Τσικούρας⁴, Γεώργιος Γαλάζιος⁴

¹Τμήμα Μαιευτικής, Σχολή Επαγγελμάτων Υγείας & Πρόνοιας (ΣΕΥΠ), Τεχνολογικό Εκπαιδευτικό Ίδρυμα (ΤΕΙ) Αθήνας, Αθήνα, ²ΡΕΑ Μαιευτική Γυναικολογική Κλινική, Αθήνα, ³Τμήμα Ιατρικής, ΠΜΣ Έρευνα στη Γυναικεία Αναπαραγωγή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ), Αθήνα, ⁴Μαιευτική-Γυναικολογική Κλινική Πανεπιστημιακού Γενικού Νοσοκομείου Αλεξανδρούπολης, Ελλάς

Georgios Iatrakis^1,2, Stefanos Zervoudis^1,2, Anastasia Bothou^2,3, Kyriakos Mitsakos-Barbagiannis², Stavros Fotopoulos², Panagiotis Peitsidis², Eirini Tomara^2,3, Panagiotis Tsikouras⁴, Georgios Galazios⁴

¹Department of Midwifery, Faculty of Health and Caring Professions, Technological Educational Institution (TEI) of Athens, Athens, ²Rea Maternity Hospital, Athens, ³Medical School, National and Kapodistrian University of Athens (NKUA), Athens, ⁴University General Hospital and University of Alexandroupolis, Alexandroupolis, Greece

2. Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R.: Therapeutic options for management of endometrial hyperplasia. J. Gynecol. Oncol. 27(1): doi: 10.3802/jgo. 2016.27.e8.

3. Ιατράκης Γ. (Εκ.): Υπερπλασία του ενδομητρίου. Στο: Ενδοκρινολογία της Γυναίκας (πρόλογος από Ζερβούδη Σ.), Αθήνα, Εκδόσεις Δεσμός, 2016

4. Fitzerald P.A.: Endocrine Disorders. In: McPhee S.J., Papadakis M.A. (Eds):Current Medical Diagnosis and Treatment. New York, McGrawHill Lange. 2011

5. Iatrakis G., Tsionis C., Antoniadis S., Kourounis G.: Effect on endometrium of combined oestrogen-progestogen replacement therapy of 1 mg 17beta-estradiol and 0.5 mg norethisterone acetate. Clin. Exp. Obstet. Gynecol. 31(1): 50-52 (2004)

6. Lurain J.R.: Uterine cancer. In: Berek JS (Ed.). Novak’s Gynecology. Philadelphia, Lippincott Williams & Wilkins 2002

7. Giuntoli R.L. Zacur Η.Α.: Management of endometrial hyperplasia. UpToDate 2016.

8. Giuntoli R.L., Zacur Η.Α.: Classification and diagnosis of endometrial hyperplasia. UpToDate 2016.

9. Lacey J.V., Jr, Sherman M.E., Rush B.B., Ronnett B.M., Ioffe O.B., Duggan M.A., Glass A.G., Richesson D.A., Chatterjee N., Langholz B.: Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J. Clin. Oncol. 28(5): 788-92 (2010)

10. Lee H., Choi H.J., Kang C.S., Lee H.J., Lee W.S., Park C.S.: Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Mod. Pathol. 25(11): 1508-1515 (2012)

11. Li X.C., Song W.J.: Endometrial Intraepithelial Neoplasia (EIN) in endometrial biopsy specimens categorized by the 1994 World Health Organization classification for endometrial hyperplasia. Asian Pac. J. Cancer Prev. 14(10): 5935-5939 (2013)

12. Emarh M.: Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study. Arch. Gynecol. Obstet. 292(6): 1339-1343 (2015)

13. Bourdel N., Chauvet P., Tognazza E., Pereira B., Botchorishvili R., Canis M.: Sampling in Atypical Endometrial Hyperplasia: Which Method Results in the Lowest Underestimation of Endometrial Cancer? A Systematic Review and Meta-analysis. J. Minim, Invasive Gynecol. 23(5): 692-701 (2016)

14. Shokouhi B.: Role of transvaginal ultrasonography in diagnosing endometrial hyperplasia in pre- and post-menopause women. Niger Med. J. 56(5): 353-356 (2015)

15. Kim M.J., Kim J.J., Kim S.M.: Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women. Obstet. Gynecol. Sci. 59(3): 192-200 (2016)

16. Yasa C., Dural O., Bastu E., Ugurlucan F.G., Nehir A., İyibozkurt A.C.: Evaluation of the diagnostic role of transvaginal ultrasound measurements of endometrial thickness to detect endometrial malignancy in asymptomatic postmenopausal women. Arch. Gynecol. Obstet. 294(2): 311-316 (2016)

17. Ramezanali F., Khalili G., Arabipoor A., Bagheri Lankarani N., Moini A.: Relationships between Serum Luteinizing Hormone Level, Endometrial Thickness and Body Mass Index in Polycystic Ovary Syndrome Patients with and without Endometrial Hyperplasia. Int. J. Fertil. Steril. 10(1): 36-41 (2016)

18. Ofinran O., Balega J.: The value of magnetic resonance imaging in investigating complex atypical hyperplasia of the endometrium. Minerva Ginecol. 68(4): 400-404 (2016)

19. Chen M., Jin Y., Li Y., Bi Y., Shan Y., Pan L.: Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int. J. Gynaecol. Obstet. 132(1): 34-38 (2016)

20. Hillard P.J.A.: Benign Diseases of the Female Reproductive Tract. In: Berek JS (ed). Berek & Novak’s Gynecology. Philadelphia, Lippincott Williams & Wilkins 2007.

21. Behnamfar F., Ghahiri A., Tavakoli M.: Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia. J. Res. Med. Sci. 19(8): 686-690 (2014)

22. Gallos I.D., Devey J., Ganesan R., Gupta J.K.: Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study. Gynecol. Oncol. 130(1): 58-63 (2013)

23. Ismail M.T., Fahmy D.M., Elshmaa N.S.: Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Reprod. Sci. 20(1): 45-50 (2013)

24. Kim M.K., Seong S.J., Kim J.W., Jeon S., Choi H.S., Lee I.H., Lee J.H., Ju W., Song E.S., Park H., Ryu H.S., Lee C., Kang S.B.: Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study. Int J Gynecol Cancer 26(4): 711-715 (2016)

25. Abu Hashim H., Ghayaty E., El Rakhawy M.: Levo-norgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am. J. Obstet. Gynecol. 213(4): 469-478 (2015)

26. Bian J., Shao H., Liu H., Li H., Fang L., Xing C., Wang L., Tao M.: Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia. Reprod. Sci. 22(6): 758-766 (2015)

27. Tasci Y., Polat O.G., Ozdogan S., Karcaaltincaba D., Seckin L., Erkaya S.: Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch. Gynecol. Obstet. 290(1): 83-86 (2014)

28. Kim M.K., Seong S.J., Kim J.W., Bae D.S., Jeon S., Kwon S.H., Lee T.S.: Management of Endometrial Hyperplasia: A Survey of Members of the Korean Gynecologic Oncology Group. Int. J. Gynecol, Cancer 25(7): 1277-1284 (2015)

29. Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K.: LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum. Reprod. 28(11): 2966-2971 (2013)

30. Gallos I.D.: Risk of relapse of endometrial hyperplasia is high and long-term treatment and follow up are recommended. BJOG 123(9): 1520 (2016)

31. Rakha E., Wong S.C., Soomro I., Chaudry Z., Sharma A., Deen S., Chan S., Abu J., Nunns D., Williamson K., McGregor A., Hammond R., Brown L.: Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am. J. Surg. Pathol. 36(1): 1683-1690 (2012)

32. Chen Y.L., Wang K.L., Chen M.Y., Yu M.H., Wu C.H., Ke Y.M., Chen Y.J., Chang Y.Y., Hsu K.F., Yen M.S.: Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese Gynecologic Oncology Group. J. Gynecol. Oncol. 24(1): 14-20 (2013)

33. Rettenmaier M.A., Mendivil A.A., Brown J.V 3rd, Abaid L.N., Micha J.P., Goldstein B.H.: Same-day discharge in clinical stage I endometrial cancer patients treated with total laparoscopic hysterectomy, bilateral salpingo-oophorectomy and bilateral pelvic lymphadenectomy. Oncology 82(6): 321-326 (2012)

34. McCausland A.M., McCausland V.M.: Long-term Clinical Outcomes Following Resectoscopic Endometrial Ablation of Non-atypical Endometrial Hyperplasia in Women With Abnormal Uterine Bleeding. J. Minim. Invasive Gynecol. 22(4): 703-704 (2015)

35. Pivano A., Crochet P., Carcopino X., Cravello L., Boubli L., Agostini A.: Risk of coexisting endometrial carcinoma in case of atypical endometrial hyperplasia diagnosed on total hysteroscopic resection. Eur. J. Obst. Gynecol. Reprod. Biol. 203: 210-213 (2016)

36. Gressel G.M., Parkash V., Pal L.: Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int. J. Gynaecol. Obstet. 131(3): 234-239 (2015)

37. Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 207(4): 266.e1-12 (2012)

38. Lara A.C., Candido E.B., Vidigal P.V., Rocha A.L.L., Carvalho-Macedo A.C., Carneiro M.M., Silva-Filho A.L.: Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice. Acta Cir. Bras. 31(4): 286-293 (2016)